

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 November 2024 (28.11.2024)



(10) International Publication Number
WO 2024/243031 A2

(51) International Patent Classification:

A61K 9/51 (2006.01) *C07D 211/62* (2006.01)
A61K 31/7105 (2006.01) *C07D 295/15* (2006.01)
A61K 31/711 (2006.01) *C07C 219/16* (2006.01)
C07C 219/04 (2006.01) *C07C 271/20* (2006.01)
C07C 229/10 (2006.01) *C07D 295/13* (2006.01)
C07D 207/16 (2006.01) *C07C 239/08* (2006.01)
C07D 211/22 (2006.01) *A61K 9/127* (2006.01)

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(21) International Application Number:

PCT/US2024/029927

(22) International Filing Date:

17 May 2024 (17.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/467,691 19 May 2023 (19.05.2023) US
63/610,628 15 December 2023 (15.12.2023) US
63/648,469 16 May 2024 (16.05.2024) US

(71) Applicant: **INTELLIA THERAPEUTICS, INC.**
[US/US]; 40 Erie Street, Cambridge, MA 02139 (US).

(72) Inventors: **MAJZOUN, Ramsey Nabil**; c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US). **MAETANI, Micah**; c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US). **IM, Siyeon**; c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US).

(74) Agent: **HALSTEAD, David, P.** et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: IONIZABLE AMINE LIPIDS

(57) Abstract: The disclosure provides ionizable lipids and lipid nanoparticle (LNP) compositions comprising ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.

WO 2024/243031 A2